Show simple item record

dc.contributor.authorVoorham, Jaco
dc.contributor.authorRoche, Nicolas
dc.contributor.authorBenhaddi, Hicham
dc.contributor.authorvan der Tol, Marianka
dc.contributor.authorCarter, Victoria
dc.contributor.authorvan Boven, Job F. M.
dc.contributor.authorBjermer, Leif
dc.contributor.authorMiravitlles, Marc
dc.contributor.authorPrice, David B.
dc.date.accessioned2018-12-12T05:22:05Z
dc.date.available2018-12-12T05:22:05Z
dc.date.issued2018-10
dc.identifier.citationVoorham , J , Roche , N , Benhaddi , H , van der Tol , M , Carter , V , van Boven , J F M , Bjermer , L , Miravitlles , M & Price , D B 2018 , ' Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK ' , BMJ Open , vol. 8 , no. 10 , e022051 , pp. 1-12 . https://doi.org/10.1136/bmjopen-2018-022051en
dc.identifier.issn2044-6055
dc.identifier.otherPURE: 141027523
dc.identifier.otherPURE UUID: 914d48e9-75e5-4bac-8fff-895cabfa76ad
dc.identifier.otherPubMed: 30368448
dc.identifier.otherScopus: 85055659550
dc.identifier.urihttp://hdl.handle.net/2164/11604
dc.descriptionAcknowledgements: The authors thank Derek Skinner, Francis Appiagyei and Tanith Hjelmbjerg of the Observational and Pragmatic Research Institute for providing assistance with data analysis. The authors also thank Ian Grieve and Bill Watkins of Ashfield Healthcare Communications, part of UDG Healthcare, for providing medical writing support. The authors thank Teva Pharmaceuticals for providing a full review of the article. Funding: This study was supported by Teva Pharmaceuticals and undertaken by OPRI (http://opri.sg). Medical writing support was funded by Teva Pharmaceuticalsen
dc.format.extent12
dc.language.isoeng
dc.relation.ispartofBMJ Openen
dc.rights© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.en
dc.subjectR Medicine (General)en
dc.subject.lccR1en
dc.titleReal-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UKen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1136/bmjopen-2018-022051


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record